fulvestrant has been researched along with erlotinib hydrochloride in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, B; Brennan, M; Dacic, S; Davenport, S; Dubinett, SM; Elashoff, D; Elashoff, RM; Garon, EB; Grogan, T; Hu, EH; Marquez-Garban, DC; Parikh, RJ; Park, DJ; Patel, R; Pietras, RJ; Press, MF; Reckamp, KL; Sadeghi, S; Siegfried, JM; Slamon, DJ; Stabile, LP; Valdes, Y; Wang, HJ; Young, PA | 1 |
| Acconcia, F | 1 |
1 trial(s) available for fulvestrant and erlotinib hydrochloride
| Article | Year |
|---|---|
Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fulvestrant; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
1 other study(ies) available for fulvestrant and erlotinib hydrochloride
| Article | Year |
|---|---|
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERĪ± Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |